[HTML] A synthetic peptide targeting the BH4 domain of Bcl-2 induces apoptosis in multiple myeloma and follicular lymphoma cells alone or in combination with …
AR Lavik, F Zhong, MJ Chang, E Greenberg… - Oncotarget, 2015 - ncbi.nlm.nih.gov
Abstract Bcl-2 inhibits apoptosis by two distinct mechanisms but only one is targeted to treat
Bcl-2-positive malignancies. In this mechanism, the BH1-3 domains of Bcl-2 form a
hydrophobic pocket, binding and inhibiting pro-apoptotic proteins, including Bim. In the other
Bcl-2-positive malignancies. In this mechanism, the BH1-3 domains of Bcl-2 form a
hydrophobic pocket, binding and inhibiting pro-apoptotic proteins, including Bim. In the other
For custom peptides, please visit www.pepmic.com. Our peptide services including but not limited to:
*Peptide Synthesis: From short peptides to long peptides, linear peptides to cyclic peptides.
*Peptide Modifications: Peptide-protein conjugation, D-amino acid peptides, isotope peptides, fluorescent peptides, multiple antigen peptides, multiple disulfide bridge peptides, phosphopeptides etc.
*Catalog Peptides: ACE Inhibitors, Amyloids & Related Peptides, Antimicrobial Peptides, Apelin Peptides, Myelin Oligodendrocyte Glycoprotein (MOG) Peptides, TAT Proteins etc.
*Peptide Salt: TFA, Desalt, Acetate, HCl.
*Peptide Purity: From crude to ＞99.5%.
*Production Capacity: From mg to kg, with a capacity of synthesizing 15,000 peptides/month.
*Peptide Library Synthesis: Alanine Scan, Overlapping, Positional Scan, T-cell Truncated, Scrambled ect.
Quick Links:
Contact Information:
Eva He
eva@pepmic.com
Pepmic Co., Ltdeva@pepmic.com
www.pepmic.com
没有评论:
发表评论